MX2022009839A - Gm-csf de accion prolongada y metodos de uso. - Google Patents

Gm-csf de accion prolongada y metodos de uso.

Info

Publication number
MX2022009839A
MX2022009839A MX2022009839A MX2022009839A MX2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A MX 2022009839 A MX2022009839 A MX 2022009839A
Authority
MX
Mexico
Prior art keywords
csf
acting
methods
long
peptides
Prior art date
Application number
MX2022009839A
Other languages
English (en)
Inventor
Feng Wang
Weijun Shen
Peter Schultz
Sean Joseph
Lei Lei
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2022009839A publication Critical patent/MX2022009839A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Materials For Medical Uses (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En este documento se describen péptidos del factor estimulante de colonias de granulocitos y macrófagos (GM-CSF) y composiciones que comprenden péptidos de GM-CSF. Estas moléculas pueden ser útiles para el tratamiento de enfermedades o afecciones neurológicas.
MX2022009839A 2020-02-12 2021-02-11 Gm-csf de accion prolongada y metodos de uso. MX2022009839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020074834 2020-02-12
PCT/US2021/017684 WO2021163346A2 (en) 2020-02-12 2021-02-11 Long-acting gm-csf and methods of use

Publications (1)

Publication Number Publication Date
MX2022009839A true MX2022009839A (es) 2022-09-05

Family

ID=77295183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009839A MX2022009839A (es) 2020-02-12 2021-02-11 Gm-csf de accion prolongada y metodos de uso.

Country Status (10)

Country Link
US (1) US20230116380A1 (es)
EP (1) EP4103618A4 (es)
JP (1) JP2023514972A (es)
KR (1) KR20220141315A (es)
CN (1) CN115461374A (es)
AU (1) AU2021220865A1 (es)
CA (1) CA3170128A1 (es)
IL (1) IL295122A (es)
MX (1) MX2022009839A (es)
WO (1) WO2021163346A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111593044A (zh) * 2019-02-20 2020-08-28 成都医学院 一种胶红酵母固定化细胞及其应用
WO2023154855A2 (en) * 2022-02-11 2023-08-17 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
WO2023196747A1 (en) * 2022-04-08 2023-10-12 Partner Therapeutics, Inc. Long-acting granulocyte macrophage-colony stimulating factor
WO2024108050A1 (en) * 2022-11-16 2024-05-23 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102807619B (zh) * 2011-06-03 2016-08-03 北京韩美药品有限公司 含有免疫球蛋白Fc片段和粒细胞-巨噬细胞集落刺激因子的复合物及其药物组合物
CN112225817A (zh) * 2013-07-11 2021-01-15 斯克利普斯研究所 卷曲螺旋免疫球蛋白融合蛋白及其组合物
EP3387019B1 (en) * 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use

Also Published As

Publication number Publication date
IL295122A (en) 2022-09-01
WO2021163346A2 (en) 2021-08-19
KR20220141315A (ko) 2022-10-19
JP2023514972A (ja) 2023-04-12
WO2021163346A3 (en) 2021-09-23
AU2021220865A1 (en) 2022-09-01
US20230116380A1 (en) 2023-04-13
CN115461374A (zh) 2022-12-09
CA3170128A1 (en) 2021-08-19
EP4103618A2 (en) 2022-12-21
EP4103618A4 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
MX2022009839A (es) Gm-csf de accion prolongada y metodos de uso.
PH12020551572A1 (en) Heterocyclic compounds as immunomodulators
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
CR20220169A (es) Heterociclos bicíclicos como inhibidores de fgfr
TW200508225A (en) Cytokine inhibitors
HK1067128A1 (en) Beta-carbolin derivatives as ptp-inhibitors
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
MX2022004759A (es) Métodos y composiciones para tratar enfermedades y trastornos hepáticos.
EP3969120A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING CANCER IN COMBINATION WITH INTERLEUKIN PROTEIN ANALOGS
MX2021013602A (es) Inhibidores de jak.
AU2003294388A1 (en) 1, 2, 3- triazole amide derivatives as cytokine inhibitors
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
CR20200649A (es) Agosnistas de tlr7
WO2021100029A3 (en) Prodrugs of fulvestrant
MX2021008712A (es) Derivados heterociclicos.
IL272253A (en) Preparations and methods for treating inflammatory conditions of the skin
MX2022011163A (es) Conjugados de polipeptidos de interleucina-2 y sus usos.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
ZA202106519B (en) Caspase inhibitors and methods of use thereof
EP4017873A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH